Acute Cerebrovascular Disease Following COVID-19: A Single Center, Retrospective, Observational Study

Li, Yanan; Wang, Mengdie; Zhou, Yifan; Chang, Jiang; Xian, Ying; Mao, Ling; Hong, Candong; Chen, Shengcai; Wang, Yong; Wang, Hailin; Li, Man; Jin, Huijuan; Hu, Bo

doi:10.2139/ssrn.3550025

Cited by 375 publications

(541 citation statements)

References 0 publications

Supporting

Mentioning

469

Contrasting

Unclassified

Order By: Relevance

“…3 However, we have found that many patients had neurological symptoms in their early stages, 4 and ischaemic stroke often happened around 2 weeks after the onset of infection. 5 Our findings have important clinical significance. If these neurological symptoms are present, test for COVID-19 may be warranted.…”

mentioning

confidence: 65%

Clinical time course of COVID-19, its neurological manifestation and some thoughts on its management

Zhou

Li²,

Wang

et al. 2020

Stroke Vasc Neurol

Self Cite

View full text Add to dashboard Cite

Coronavirus disease-2019 (COVID‐19) has become a global pandemic. COVID-19 runs its course in two phases, the initial incubation phase and later clinical symptomatic phase. Patients in the initial incubation phase often have insidious clinical symptoms, but they are still highly contagious. At the later clinical symptomatic phase, the immune system is fully activated and the disease may enter the severe infection stage in this phase. Although many patients are known for their respiratory symptoms, they had neurological symptoms in their first 1–2 days of clinical symptomatic phase, and ischaemic stroke occurred 2 weeks after the onset of the clinical symptomatic phase. The key is to prevent a patient from progressing to this severe infection from mild infection. We are sharing our experience on prevention and management of COVID-19.

show abstract

mentioning

confidence: 65%

Clinical time course of COVID-19, its neurological manifestation and some thoughts on its management

Zhou

Li²,

Wang

et al. 2020

Stroke Vasc Neurol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Initial findings point towards a hypercoagulable state in COVID-19 patients. High levels of thrombosis and inflammation serum markers, such as D-dimers, fibrinogen and C-reactive protein, have been reported [7][8][9].…”

Section: Discussionmentioning

confidence: 99%

Impact of the COVID‐19 outbreak on acute stroke pathways – insights from the Alsace region in France

Pop

Quenardelle

Hasiu

et al. 2020

Euro J of Neurology

View full text Add to dashboard Cite

Background and purposeTo date, no study has attempted to quantify the impact of the COVID‐19 outbreak on the incidence and treatment of acute stroke.MethodsThis was a retrospective review of acute stroke pathway parameters in all three stroke units in the Alsace region during the first month of the outbreak (1–31 March 2020), using the similar period from 2019 as a comparator. A secondary detailed analysis of all stroke alerts and stroke unit admissions was performed in the centre with the largest case volume.ResultsCompared to the same period in 2019, in March 2020 there were 39.6% fewer stroke alerts and 33.3% fewer acute revascularization treatments [40.9% less intravenous thrombolysis (IVT) and 27.6% less mechanical thrombectomy (MT)]. No marked variation was observed in the number of stroke unit admissions (−0.6%). The proportion of patients with acute revascularization treatments (IVT or MT) out of the total number of stroke unit admissions was significantly lower in March 2020 (21.3%) compared to 2019 (31.8%), P = 0.034. There were no significant differences in time delays or severity of clinical symptoms for patients treated by IVT or MT, nor in the distribution of final diagnosis amongst stroke alerts and stroke unit admissions.ConclusionThese results suggest that the overall incidence of stroke remained the same, but fewer patients presented within the therapeutic time window. Increased public awareness and corrective measures are needed to mitigate the deleterious effects of the COVID‐19 outbreak on acute stroke care.

show abstract

“…14 Additionally, systemic inflammation related metabolic and homeostatic derangements contributes to encephalopathy, but it may also predispose one to stroke, which has been noted to occur more commonly in severe clinical presentations. 25 Besides the acute neurological manifestations of SARS CoV-2 infection, further monitoring for long-term sequelae may reveal viral contribution in pathophysiology or increased risk for neuroinflammatory and neurodegenerative diseases. It has been shown in animal and human studies that coronaviruses could possibly be implicated in the pathogenesis of Parkinson's disease, 26 acute disseminated encephalomyelitis, 27 or multiple sclerosis.…”

Section: Clinical Pathophysiological Implicationsmentioning

confidence: 99%

Letter to the Editor Regarding the Viewpoint “Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host–Virus Interaction, and Proposed Neurotropic Mechanism”

Toljan

2020

ACS Chem. Neurosci.

View full text Add to dashboard Cite

Metrics & More Article Recommendations Dear Editor, I have read with interest the viewpoint entitled Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host−Virus Interaction, and Proposed Neurotropic Mechanisms by Baig et al. 1 This letter is supposed to supplement the aforementioned article with expanded scope on pathophysiological mechanisms which could prove salient in elucidating pathogenesis, seeking treatment, or considering clinical implications.

show abstract

Acute Cerebrovascular Disease Following COVID-19: A Single Center, Retrospective, Observational Study

Cited by 375 publications

References 0 publications

Clinical time course of COVID-19, its neurological manifestation and some thoughts on its management

Clinical time course of COVID-19, its neurological manifestation and some thoughts on its management

Impact of the COVID‐19 outbreak on acute stroke pathways – insights from the Alsace region in France

Letter to the Editor Regarding the Viewpoint “Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host–Virus Interaction, and Proposed Neurotropic Mechanism”

Contact Info

Product

Resources

About